STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation
Title and abstract	1	(*a*) **A Cross-sectional study design, can be found on Page no. 1 of the manuscript**
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found: **can be found on Page no. 1**
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported- **can be found on Page no. 2 & 3, line no. 65 to 71**
Objectives	3	State specific objectives, including any prespecified hypotheses **can be found on Page no. 3, line no. 68 to 71**
Methods		
Study design	4	Present key elements of study design early in the paper **can be found on Page no. 3, line no. 80 to 81**
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection **can be found on Page no. 3, line no. 90 to 92; Page no. 4 line no. 129-130**
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants **can be found on Page no. 3, line no. 87-95**
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable **can be found on Page no. 3 &4, line no. 97-120**
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group **can be found on Page no. 3 &4, line no. 87-120**
Bias	9	Describe any efforts to address potential sources of bias, **there were no potential sources of bias in this study**
Study size	10	Explain how the study size was arrived at **can be found on Page no. 3, line no. 87-88**
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why **can be found on Page no. 3, line no. 87-95**
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding
		(*b*) Describe any methods used to examine subgroups and interactions
		(*c*) Explain how missing data were addressed
		(*d*) If applicable, describe analytical methods taking account of sampling strategy
		(*e*) Describe any sensitivity analyses **can be found on Page no. 4&5, line no. 134-144**
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed

		can be found on Page no. 3, line no. 87-95
		(b) Give reasons for non-participation at each stage **Page no. 6, line no. 174-180**
		(c) Consider use of a flow diagram **NA**
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders **Page no. 3, line no. 87-95;**
		(b) Indicate number of participants with missing data for each variable of interest **Page no. 6, line no. 174-180**
Outcome data	15*	Report numbers of outcome events or summary measures **Page no. 4, line no. 122-127; Page no. 4, line no. 97-120**
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(*b*) Report category boundaries when continuous variables were categorized
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period **All included from Page no. 5-7, line no. 166-209**
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses **NA**
Discussion		
Key results	18	Summarise key results with reference to study objectives **Page no. 7-10, line no. 211-294**
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias **Page no. 10, line no. 296-303**
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence **Page no. 7-10, line no. 211-294; Page no. 10, line no. 296-303**
Generalisability	21	Discuss the generalisability (external validity) of the study results **Page no. 10, line no. 299-303**
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based **Page no. 11, line no. 335&6**

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.